Accuray Secures $10M to Pave the Way for Expanded Curative Radiation Therapy

Accuray is thrilled to announce a major milestone in our journey to revolutionize cancer care with a successful funding round of $10,000,000. This investment marks a significant step forward in our mission to expand the curative power of radiation therapy and improve the lives of patients worldwide. At Accuray, we work passionately every day to push the boundaries of medical innovation, and this fresh capital will enable us to further develop and refine our cutting-edge treatment systems, including the world-renowned CyberKnife, Radixact, and TomoTherapy. Our goal is not only to enhance the precision and effectiveness of our radiation therapy solutions but also to broaden their accessibility, ensuring that more communities and institutions can benefit from our breakthrough technologies. The new funding will be dedicated to accelerating research and development, optimizing our existing treatment platforms, and integrating next-generation innovations that can offer more personalized treatment strategies for patients battling cancer. We are committed to harnessing this opportunity to extend our reach, forge impactful collaborations, and ultimately contribute to a future where life-saving radiation therapy is available to patients in need, regardless of geographical limitations. Furthermore, we believe that every advancement in technology carries the potential to transform the patient experience – from diagnosis to recovery – making our efforts not just a scientific pursuit, but also a profound human endeavor. Join us in celebrating this achievement and our continued commitment to innovation under the banners of #AccurayExpandRT, #CyberKnife, #Radixact, #TomoTherapy, and #AccurayExchange as we embark on the next chapter of our journey to make a meaningful difference in the fight against cancer.